• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Trevi Therapeutics Inc.

    4/21/26 4:00:11 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    DEFA14A
    0001563880falseDEFA14A00015638802024-01-012024-12-31

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    TREVI THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

    Your Vote Counts! TREVI THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 2, 2026 11:59 PM ET TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR NEW HAVEN, CT 06510 V93497-P48049 You invested in TREVI THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2026. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote in Advance of the Meeting Vote by June 2, 2026 11:59 PM ET Visit www.ProxyVote.com Vote Virtually at the Meeting* June 3, 2026 11:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/TRVI2026 *Please check the meeting materials for any special requirements for meeting attendance.

    img92490068_0.jpg

     

     


     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials, which contain important information and are available to you on the Internet at www.proxyvote.com. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting of Stockholders. Nominee: 1a.Michael Heffernan For 2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. Approval, on an advisory basis, of the compensation paid to our named executive officers. For 4. Approval of the Trevi Therapeutics, Inc. Amended and Restated 2019 Stock Incentive Plan. For 5. Approval of an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares. For NOTE: Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V93498-P48049

    img92490068_1.jpg

     


    Get the next $TRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    11/13/2025$13.00Outperform
    Leerink Partners
    8/21/2025$18.00Overweight
    Morgan Stanley
    7/1/2025$25.00Overweight
    Cantor Fitzgerald
    5/28/2025$21.00Buy
    H.C. Wainwright
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    More analyst ratings

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Trevi Therapeutics with a new price target

    Leerink Partners initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $13.00

    11/13/25 9:10:57 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Trevi Therapeutics with a new price target

    Morgan Stanley initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $18.00

    8/21/25 8:19:41 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Trevi Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:23:22 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Development Officer Cassella James V

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    2/20/26 4:17:06 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Galletta Christopher

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    2/20/26 4:16:45 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Sciascia Thomas

    4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

    2/20/26 4:16:27 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    SEC Filings

    View All

    SEC Form DEF 14A filed by Trevi Therapeutics Inc.

    DEF 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)

    4/21/26 4:00:16 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Trevi Therapeutics Inc.

    DEFA14A - Trevi Therapeutics, Inc. (0001563880) (Filer)

    4/21/26 4:00:11 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Trevi Therapeutics Inc.

    424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)

    4/17/26 4:17:51 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

    NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of

    4/20/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

    NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of t

    4/16/26 10:42:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Proposed Public Offering of Common Stock

    NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of the shares of its common

    4/16/26 4:08:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    View All

    Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

    Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.  www.trevitherapeutics.com (PRNewsfoto/Trevi

    12/4/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

    NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

    9/30/24 5:30:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

    Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig

    3/17/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025.  Conference Call and WebcastTo register for the live co

    3/10/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF I

    11/13/25 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/13/24 4:30:24 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

    SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/8/24 6:57:55 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care